Sphera Funds Management LTD. raised its position in Versartis, Inc. (NASDAQ:VSAR) by 25.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 377,524 shares of the biopharmaceutical company’s stock after buying an additional 77,524 shares during the period. Versartis makes up 1.1% of Sphera Funds Management LTD.’s portfolio, making the stock its 18th largest position. Sphera Funds Management LTD. owned 1.07% of Versartis worth $6,588,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Victory Capital Management Inc. acquired a new stake in shares of Versartis during the first quarter worth about $563,000. Perceptive Advisors LLC raised its stake in shares of Versartis by 6.1% in the first quarter. Perceptive Advisors LLC now owns 4,407,317 shares of the biopharmaceutical company’s stock worth $94,096,000 after buying an additional 253,632 shares during the period. Bank of New York Mellon Corp raised its stake in shares of Versartis by 21.1% in the first quarter. Bank of New York Mellon Corp now owns 164,247 shares of the biopharmaceutical company’s stock worth $3,506,000 after buying an additional 28,666 shares during the period. Oxford Asset Management raised its stake in shares of Versartis by 240.9% in the first quarter. Oxford Asset Management now owns 124,744 shares of the biopharmaceutical company’s stock worth $2,663,000 after buying an additional 88,151 shares during the period. Finally, AlpInvest Partners B.V. acquired a new stake in shares of Versartis during the first quarter worth about $706,000. Institutional investors own 78.77% of the company’s stock.

Shares of Versartis, Inc. (NASDAQ VSAR) traded up 2.11% during trading on Friday, hitting $19.40. The stock had a trading volume of 433,207 shares. Versartis, Inc. has a one year low of $9.05 and a one year high of $24.00. The company’s market cap is $690.21 million. The stock’s 50-day moving average price is $18.06 and its 200-day moving average price is $18.40.

Versartis (NASDAQ:VSAR) last posted its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by $0.20. On average, equities research analysts forecast that Versartis, Inc. will post ($3.49) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Sphera Funds Management LTD. Acquires 77,524 Shares of Versartis, Inc. (VSAR)” was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.watchlistnews.com/sphera-funds-management-ltd-acquires-77524-shares-of-versartis-inc-vsar/1538195.html.

VSAR has been the topic of a number of recent research reports. Zacks Investment Research lowered shares of Versartis from a “hold” rating to a “sell” rating in a research note on Wednesday, August 2nd. Piper Jaffray Companies set a $26.00 price target on shares of Versartis and gave the stock a “buy” rating in a research note on Tuesday, June 27th. BidaskClub upgraded shares of Versartis from a “hold” rating to a “buy” rating in a research note on Monday, July 24th. Cantor Fitzgerald set a $34.00 price target on shares of Versartis and gave the stock a “buy” rating in a research note on Thursday, July 27th. Finally, Canaccord Genuity set a $28.00 price target on shares of Versartis and gave the stock a “buy” rating in a research note on Friday, July 28th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $27.88.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Want to see what other hedge funds are holding VSAR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Versartis, Inc. (NASDAQ:VSAR).

Institutional Ownership by Quarter for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.